Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01290393 · ClinicalTrials.gov registry record
Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada
A clinical trial, sponsored by GlaxoSmithKline.
- Terminated
- Registry status
- 2
- Enrollment target
NCT01290393 is a clinical trial that was terminated before completion, run by GlaxoSmithKline. The registered enrollment target is 2 participants.
The verdict
NCT01290393 was terminated before completion, sponsored by GlaxoSmithKline.
- TERMINATED
- Registry status
- 2 participants
- Enrollment target
Study Summary
This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort, i.e. women with last menstrual period between 120 days and 18 months after the last CERVARIX or GARDASIL dose.
Interventions
- OTHER Data collection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-09-26 |
| Est. Completion | 2012-12-20 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01290393
The ClinicalTrials.gov registry entry for NCT01290393 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Data collection is the first listed.
NCT01290393 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01290393 about?
NCT01290393 is a clinical study titled "Post-marketing Study to Assess the Safety of CERVARIX When Used in the United States and in Canada". This study will assess the risk of spontaneous abortion during weeks 1-19 of gestation, and other pregnancy outcomes, in an Exposed vaccinated cohort, i.e. women with last menstrual period between 30 days before and 90 days after any dose of CERVARIX, when compared to a Non-exposed vaccinated cohort...
What is the current status of trial NCT01290393?
This trial is currently terminated. The enrollment target is 2 participants. The study started on 2011-09-26. Estimated completion is 2012-12-20.
What interventions are being tested in trial NCT01290393?
The interventions under investigation include: Data collection (OTHER).
Who is sponsoring clinical trial NCT01290393?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.